Background: Ependymal tumors in adults are rare, accounting for less than 4 % of primary tumors of the central nervous system in this age group. The low prevalence of intracranial ependymoma in adults limits the ability to perform clinical trials. Therefore, treatment decisions are based on small, mostly retrospective studies and the role of chemotherapy has remained unclear. Methods: We performed a retrospective study on 17 adult patients diagnosed with intracranial World Health Organisation grade II or III ependymoma, who were treated with chemotherapy at any time during the disease course. Benefit from chemotherapy was estimated by applying Macdonald criteria. Progression-free (PFS) and overall survival (OS) were calculated from start of chemotherapy, using the Kaplan-Meier method. Results: Eleven patients had supratentorial and 6 infratentorial tumors. Ten patients were treated with temozolomide (TMZ), 3 with procarbazine/lomustine/vincristine (PCV), 3 with platinum-based chemotherapy and 1 patient received epirubicin/ifosfamide. Response rates were as follows: TMZ 8/10 stable disease; PCV 3/3 stable disease; platinum-based chemotherapy 1/3 partial response; epirubicin/ifosfamide 1/1 complete response. PFS rates at 6, 12 and 24 months were 52.9, 35.3 and 23.5 %. OS rates at 6, 12 and 24 months were 82.4, 82.4 and 70.1 %. There was no indication for a favourable prognostic role of O 6 -methylguanyl-DNA-methyltransferase (MGMT) promoter methylation which was detected in 3/12 investigated tumors. Conclusions: Survival outcomes in response to chemotherapy in adult intracranial ependymoma patients vary substantially, but individual patients may respond to any kind of chemotherapy. There were too few patients to compare survival data between chemotherapeutic subgroups.
Background
Ependymomas are a histologically, biologically and clinically heterogenous group of glial tumors that show histological features of ependymal differentiation and preferentially are located in the cerebral ventricles or the spinal cord. In total, ependymomas account for 6.8 % of all gliomas, with the relative frequency being higher in children compared to adults [1] . In adults, ependymomas are less than 4 % of primary central nervous system tumors [2] and are found more often in spinal (46 %) than infra-(35 %) or supratentorial (19 %) locations [3] . These tumors are classified by the World Health Organisation (WHO) into 3 grades [4] . The prognostic relevance of the histopathological distinction between WHO grade II versus WHO grade III ependymomas has remained controversial [2, 5] . In comparison to WHO grade II ependymomas, WHO grade III ependymomas are associated with increased risk of treatment failure [3] .
The low prevalence of intracranial ependymoma in adults limits opportunities to perform large clinical trials. Thus, treatment recommendations are based on small, mostly retrospective studies. Surgical resection is the most important therapeutic intervention for intracranial ependymomas [2] . Extent of resection has been associated with increased progression-free survival (PFS) and overall survival (OS) in most series [3, [6] [7] [8] . Adjuvant radiotherapy (RT) is recommended for patients diagnosed with anaplastic (WHO grade III) ependymoma [2, 9] , whereas the role of RT in patients with WHO grade II ependymoma is discussed controversially. While resection followed by irradiation as first-line therapy is considered for posterior fossa ependymoma [10] , RT for supratentorial ependymoma is commonly used only when surgical resection has been incomplete [2, 3, 11] . The role of chemotherapy (CT) for intracranial ependymoma in adults remains unclear. A variety of chemotherapeutic drugs has been investigated in the past, mostly in retrospective studies or case reports. Selected case reports demonstrate response to temozolomide (TMZ) in recurrent WHO grade III ependymoma [12, 13] or recurrent WHO grade II and III ependymomas [14] . Activity of TMZ was also described in a retrospective study, analyzing recurrent WHO grade II ependymomas, refractory for platinum-based chemotherapy [15] , as well as in a prospective phase II study in ependymoma patients treated with TMZ and lapatinib at tumor recurrence [16] . Brandes and colleagues compared patients with recurrent WHO grade II ependymomas treated with cisplatin-based CT or treated with another kind of CT, demonstrating no significant differences regarding PFS or OS [17] . Here we performed a retrospective analysis of outcome data in 17 adult patients diagnosed with intracranial WHO grade II or III ependymoma and treated with chemotherapy at any time during their disease course.
Methods

Patients and tumors
In accordance with approval from the appropriate Institutional Review Boards, the surgical specimens and clinical records were retrieved from 17 patients treated at the University Hospital Zurich, Zurich, Switzerland, or at one of the eight University Hospitals in Germany participating in the German Glioma Network (GGN) (http://www.gliomnetzwerk.de). All patients gave written informed consent according to the research proposals approved by the Institutional Review Boards of the participating institutions (University of Zurich, Switzerland; Universities of Bochum, Bonn, Dresden, Düsseldorf, Hamburg, Heidelberg, Munich and Tübingen, all Germany). All tumors were classified and graded according to the WHO classification of tumors of the central nervous system [4] . The O 6 -methylguanyl-DNA-methyltransferase (MGMT) promoter methylation status was determined by methylation-specific polymerase chain reaction in 12 tumors [18] . Epidemiological and treatment data were taken from patient health records. Radiological response rates to chemotherapy were documented using Macdonald criteria [19] as foreseen in the German Glioma Network study protocol.
Statistics
PFS and OS curves were estimated by the Kaplan-Meier method. PFS was calculated from the date of first chemotherapy to the date of progression. OS was measured from the date of first chemotherapy to the date of death. Patients without confirmed death were censored for OS at the last follow-up visit. Patients without documented progression were censored at the last follow-up visit for PFS. Survival-related analyses were calculated with the log-rank test. A cox proportional hazard model was used for univariate analysis, to test the association of clinical predictors with survival outcomes from start of chemotherapy. All statistical tests were two-tailed, and a p value of 0.05 was set as statistically significant. All statistical analyses were performed using Prism 6 (GraphPad Software) or Statistics 22 (SPSS software). Table 2 .
Results
Patient characteristics
At time of recurrence 2 patients initially diagnosed with anaplastic ependymoma were diagnosed with sarcoma (patient 5) or gliosarcoma (patient 9) ( Table 2 ). Both patients had been previously treated with RT. At recurrence patient 5 was treated with 7 cycles of epirubicin/ifosfamide and demonstrated a complete response (CR) with no evidence of recurrence during follow-up of 8.8 years. Patient 9 was treated with 9 cycles of TMZ, best response was ). Group sizes were too small for formal comparisons, but not obvious signal of activity of a particular regimen became apparent.
MGMT promoter methylation and survival in intracranial ependymoma
The MGMT promoter methylation status of the tumor was available in 12 patients ( Patients were divided into two groups, defined by age, tumor localization, gender, KPS and MGMT promoter methylation status, and a log-rank survival analysis was performed. This analysis revealed supratentorial tumors to be associated with inferior survival ( Table 3 , Additional file 1: Table S1 ). Univariate analysis using the cox proportional hazard model from start of first CT treatment was performed to identify factors associated with overall survival. The results of these analyses are summarized in Table 3 for all 17 patients initially diagnosed with ependymoma, and in Additional file 1: Table S1 for the remaining patient cohort when the two patients diagnosed with sarcoma or glioblastoma at recurrence were excluded. Age, tumor localization, gender, KPS and the MGMT promoter methylation status were not identified as risk factors for death in both patient cohorts ( Table 3 , Additional file 1: Table S1 ).
Discussion
Intracranial ependymoma is a rare disease in adults [2] . While the role of surgical resection and RT for tumor control is undisputed [2, 3, [6] [7] [8] [9] 11] , little is known about the significance of CT. Here we retrospectively analyzed 17 adult patients with intracranial WHO grade II or grade III ependymomas to investigate the impact of chemotherapy on the disease course. Most patients (n = 10) received TMZ as their first chemotherapeutic treatment ( Table 1) . Two of these patients received a combined treatment of irradiation and TMZ (TMZ/RT → TMZ) [20] at diagnosis. Median PFS for these two patients was low with 3 months as it was for median OS with 27 months. The other 8 patients were treated with TMZ at recurrence and the best response was SD. Thus, TMZ demonstrated some activity in intracranial ependymoma patients, especially at time of recurrence. Of note, there is one prospective study presented at the American Society of Clinical Oncology (ASCO) in 2005, which included patients with recurrent WHO grade II and III ependymomas. Activity of TMZ treatment in these patients was as follows (best response: median PFS): CR (n = 2): 9-48 months; PR (n = 3): 4-15 months; SD (n = 5): 7-44 months [14] (Table 4 ). Less optimal results were reported by Chamberlain and Johnston for TMZ treatment of 25 patients with recurrent WHO grade II ependymomas, refractory to platinum-based chemotherapy, who demonstrated a median PFS of 3 months, and best responses of PR in 1 patients and SD in 9 patients with a median OS of 3 months [15] (Table 4 ). Moreover, results of a prospective trial, including 24 patients diagnosed with WHO grade II ependymoma and 18 patients diagnosed with anaplastic ependymoma, treated with TMZ plus lapatinib, were presented at the annual meeting of the Society of Neurooncology (SNO) in 2014 [16] . Lapatinib targets the epidermal growth factor receptor (ErbB1) and the related family member HER-2/neu (ErbB2) on the cell surface of the tumor cells. Median PFS was 45 weeks for patients diagnosed with grade II, and 25.3 weeks for patients diagnosed with grade III ependymomas. Best response rates were CR in one patient diagnosed with anaplastic astrocytoma and PR in 1 patient diagnosed with anaplastic astrocytoma and 2 patients diagnosed for ependymoma WHO grade II. Several patients showed at least SD. First results of a molecular classification revealed a correlation of response with ErbB2 expression [16] . In addition, there are two case reports of patients diagnosed with recurrent anaplastic ependymoma, describing a median PFS after TMZ treatment of 5 and 9 months [12, 13] (Table 4 ). One reason for the possible failure of TMZ in patients with intracranial glioma is a non-methylated MGMT promoter [21] . Ependymomas may express high levels of MGMT [22] , predicting less benefit from TMZ-based CT. Only 3 out of 12 ependymoma patients included in our study had tumors with a methylated MGMT promoter. Median PFS in these 3 patients was in the range of 1-6 months and thus low, and one of these patients treated with TMZ demonstrated no response. Our small dataset fails to indicate a favorable prognostic role of MGMT promoter methylation in adult ependymoma. The other chemotherapeutic regimens were platinumbased CT (n = 3) or PCV (n = 3), showing a median PFS of 4 or 6 months and response rates as follows: PR (1 patient) or SD (3 patients) ( Table 2 ). Brandes et al. published a retrospective study in 2005, analyzing 28 ependymoma patients (WHO grade II and III); 13 patients were treated with platinum-based CT, demonstrating best responses of 2 CR, 2 PR and 7 SD, and a median PFS of 9.9 months in comparison to 15 patients treated with CT without cisplatin, demonstrating best responses of 2 PR and 11 SD, and a median PFS of 10.9 months [17] . PFS data were similar to the data reported here. Although response rates were lower in the group of patients treated with any other CT, but without cisplatin, survival curves (PFS and OS) did not differ. Three of the 15 patients were treated with PCV, showing best responses with 1 PR, and 2 SD, therefore demonstrating a similar response as reported here (Tables 2 and 4 ).
Beyond these mentioned standard chemotherapeutic drugs, there is need for patient stratification based on molecular markers to identify ependymoma subgroups as well as subgroup-specific therapies, as recently described by Pajtler et al. [23] . Since all pre-clinical in vivo models tested for chemotherapy so far showed only reduced sensitivity towards these standard chemotherapeutic drugs, targeted therapies (e.g. epidermal growth factor receptor (EGFR) inhibitors, histone deacetylase (HDAC) inhibitors) are in the focus of research at the moment and need to be investigated [24] .
Review of the literature showed a case report demonstrating a CR and a median PFS of 17 months in an adult patient with recurrent anaplastic intracranial ependymoma after treatment with tamoxifen and isotretinoin [25] . Beyond classical CT, Green et al. reported outcome data in 8 recurrent WHO grade II and III intracranial ependymomas which were treated with bevacizumab at time of recurrence. Promising response rates with 6 PR and 1 SD and a median PFS of 6.4 and OS of 9.4 months were described [26] .
Two patients in our study were initially diagnosed with anaplastic ependymoma and at recurrence demonstrated sarcoma or gliosarcoma ( Table 2 ). Both patients had been treated with RT in-between and had supratentorial tumors. A common origin for the initial and the recurrent tumor has to be considered, since there are reports in the literature demonstrating identical genetic mutations in both glial and sarcomatous compartments of gliosarcomas [16, 27, 28] . Interestingly, both patients appeared to derive benefit from chemotherapy.
Kaplan-Meier survival analysis revealed supratentorial tumor location as a parameter associated with inferior survival (Table 3 ). Supratentorial tumor localization has been described as significantly increasing risk of early death [29] , therefore underlining the clinical aggressiveness of supratentorial ependymomas in adults that is independent from CT treatment. Our data suggest that survival outcomes in response to chemotherapy in adult intracranial ependymoma patients vary substantially, but individual patients may respond to any kind of chemotherapy.
Conclusions
The main limitation of our study is its retrospective design and the low number of patients in each chemotherapeutic subgroup. In summary, this retrospective study provides data supporting activity of TMZ in recurrent anaplastic ependymoma; however, there are also promising response rates in patients treated with platinumbased CT or PCV. Because of the notably individual survival outcomes after chemotherapeutic treatment in adult ependymoma patients with intracranial disease, prospective studies are urgently needed to identify patient subgroups that will benefit from individual chemotherapeutic treatments. Yet, this report suggests that at least one line of CT should be offered to ependymoma patients who are no longer candidates for surgery or RT.
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